Aldeyra Therapeutics Hosts Conference Call and Webcast to Announce Top Results from Phase 3 TRANQUILITY-2 Dry Eye Trial

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) announced today that it will host a webcast and conference call on Wednesday, June 8, 2022 at 8:00 a.m. (ET) to provide initial results from Phase 3 TRANQUILITY -2 Trial of reproxalap in dry eye.

The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 879247. A live audio webcast of the conference call will also be accessible from the “Investors and Media” section of Aldeyra’s website at

After the live webcast, the event will remain archived on the Aldeyra website for 90 days.

About Aldeyra

Aldeyra develops innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immune systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokines, systemic mediators of inflammation known as RASPs (reactive aldehyde species). Reproxalap is undergoing phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical trials for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (0.8% intravitreal methotrexate), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit and follow us on LinkedIn, Facebook and Twitter.

Michael P. Boser